◆英語タイトル：Angioplasty Balloons Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
The Angioplasty Balloons market was valued at about USD 2,550 million in 2020 and is expected to reach USD 2,975 million in 2026, registering a CAGR of nearly 3.5% during the forecast period.
According to a research article published in September 2020, Cardiac surgery during the COVID-19 era carries a combined risk for cardiac patients who are at greater risk for the complications of COVID-19, and for the healthcare workers associated with these patients. Moreover, the American College of Surgeons and the American Society of Anesthesiologists recommended suspending elective cardiac surgery for a minimum of 14 days after the negative report of the COVID-19 suspected patient. Thus, in view of the several factors surrounding COVID-19, elective angioplasty surgeries are expected to be suspended which is going to affect the adoption of angioplasty balloons and the market can have slight or little growth.
However, with the increasing burden of cardiovascular diseases and the preference toward minimally invasive surgery, balloon angioplasty has become the method of choice to treat patients suffering from coronary and peripheral artery diseases. Cardiac diseases around the globe are increasing at an enormous rate and this calls for precise treatment alternatives with high success rates. According to the World Health Organization in 2017, the prevalence of cardiovascular diseases was found to be among 485.6 million population, and an estimated 17.9 million people die due to cardiovascular diseases worldwide each year. This represents 35% of global deaths. Additionally, 85% of these cardiovascular disease deaths are due to heart attack and stroke. Similarly, according to the Global Health and Wellness Report published in 2018, nearly 40% of the adult population in the United States were diagnosed with a cardiovascular condition United States. Also, as per the Foundation de France, one in three people in France represents a major risk for having cardiovascular disease. Approximately 120,000 heart attacks and over 130,000 strokes occur in France each year.
Additionally, factors such as the rising prevalence of lifestyle-related disorders and increasing geriatric populations are fuelling the growth of the angioplasty balloons market. For instance, according to the World Aging Population Report, in 2019, the number of people aged 65 years and above had been recorded to be around 702.9 million, globally, and the number is expected to reach 1548.9 million by 2050. Thus, with an increase in the geriatric population, the prevalence of chronic diseases, especially cardiovascular disease is also expected to increase, which in turn results in hospital admissions and surgeries. Also, there has been increasing clinical development to advance the existing technology as well as to explore the new opportunities by key players. For instance, in November 2018, Koninklijke Philips N.V. initiated patient enrolment for its Stellarex ILLUMINATE below-the-knee (BTK) investigational device exemption (IDE) and commenced clinical trial in the United States. The study was aimed to evaluate the safety and effectiveness of the Stellarex 0.014 drug-coated angioplasty balloon to percutaneous transluminal angioplasty (PTA) in critical limb ischemia (CLI) patients. These players are increasing their focus on newer angioplasty balloons made of different materials and new products and are coming up with new and innovative product launches to propel the market growth. However, high costs and the post-operational complications associated with angioplasty are expected to hamper the market growth.
Key Market Trends
Hospitals Segment is Expected to Dominate the Angioplasty Balloons Market
The hospital segment is expected to hold a major share of the overall angioplasty balloons market. The factors responsible for the dominance of this segment are advanced healthcare infrastructure, increasing availability of skilled labor, and affordability. For instance, in 2018, as per the report published by Advanced Medical Technology Association (AdvaMed), India, the government’s move to cap the maximum price of various cardiovascular surgical instrument has resulted in reduced angioplasty procedure costs in tier 1 and metro corporate chains and standalone private hospitals up to 18%, in India which is one of the major hubs of cardiovascular disease. In addition, owing to substantial growth in the geriatric population suffering from lifestyle diseases, such as atherosclerosis and heart failure, is expected to increase the patient pool and enhance revenue generations of the hospitals.
Moreover, compared to conventional surgeries, the several advantages of minimally invasive surgeries such as reduced surgical pain, injury, scarring, hospital stay, higher accuracy, and speedy recovery time are encouraging more patients to opt for minimally invasive balloon angioplasty surgeries. As per the data reported by the American College of Cardiology, approximately 1.2 million angioplasties a year in the United States. Moreover, the high accessibility and affordability of hospitals, as compared to the specialty clinics, are expected to attract a large patient population.
However, due to the current COVID-19 situation, limited movement of the population in the hospital is observed. Unless and until it is not emergent the population is avoiding undergoing any kind of surgery or diagnostic procedures to limit the risk of the infection In addition, hospitals have also transferred their personnel availability from cardiac departments to other departments in need such as ED or intensive care units (ICU). All these factors are expected to affect the market growth, but this slowed down in growth is anticipated to be temporary, and in the long run, the market is forecasted to have significant growth.
The graph below suggested that the prevalence of cardiovascular disease s continuously surging in the developed regions such as North America owing to the change in lifestyle habits and the high burden of obesity among the population. This surge in the disease prevalence is expected to boost the demand for the angioplasty balloon market.
North America is the Largest Market for Angioplasty Balloons Market
North America accounted for the maximum revenue share in the angioplasty balloons market. The presence of key industry players, the rising healthcare expenditure, and a growing number of percutaneous coronary interventions are the primary drivers of the region. According to the American Heart Association Research Report 2018, heart disease accounted for 1 in 7 deaths in the United States in that year. Among the cardiovascular diseases, coronary heart disease was the leading cause of deaths, attributing to 43.8% of deaths, followed by stroke (16.8%), heart failure (9.0%), high blood pressure (9.4%), diseases of the arteries (3.1 %), and other cardiovascular diseases (17.9%) in the United States. Thus, there exists a higher demand for better treatment with advanced medical devices, which acts as a major factor driving the studied market.
In addition, increased investments and the inorganic growth strategies by major market players in the region are the factors estimated to augment the market during the forecast years. For instance, in 2018, Teleflex, a United States-based company signed an agreement to acquire the assets of QT Vascular. Under the agreement, Teleflex paid USD 98.4 million and USD 26.2 million for the non-drug coated coronary products, USD 65.6 million for the drug-coated coronary product, and up to an additional USD 6.6 million upon the achievement of certain sales revenue milestones. All these developments are further expected to increase the robust product line of the market and are anticipated to offer lucrative growth opportunities to the region.
Angioplasty Balloons market is highly fragmented with the presence of many prominent players. Key players of the market are focused on strategic mergers collaborations, and acquisitions in order to enhance their market share. Major players in order to have a competitive edge over the other players are also focusing on R&D to improve product quality and minimize manufacturing costs, developing novel products to improve patient compliance and safety. For instance, in August 2018, B. Braun Melsungen AG showed the top-line results from its clinical trials pipeline for its drug-coated balloon ‘SeQuent Please’ for percutaneous transluminal coronary angioplasty.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Cardiovascular Diseases
4.2.2 Increasing Preference for Minimally Invasive Procedures and Technological Advancements
4.3 Market Restraints
4.3.1 High Costs Associated with the Procedure
4.3.2 Complications Associated with Angioplasty Procedures
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Normal Balloons
5.1.2 Cutting/Scoring Balloons
5.1.3 Drug Eluting Balloons
5.2 By Application
5.2.1 Coronary Angioplasty
5.2.2 Peripheral Angioplasty
5.3 By End User
5.3.2 Ambulatory Surgical Centers
5.3.3 Other End Users
5.4.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.4.4 Middle East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.4.5 South America
126.96.36.199 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.3 Becton Dickinson
6.1.4 Medtronic Plc
6.1.5 Boston Scientific Corporation
6.1.6 Braun Melsungen AG
6.1.7 Cook Medical
6.1.8 Cordis (Cardinal Health)
6.1.9 Endocor GmbH
6.1.10 INFINITY Angioplasty Balloon
6.1.11 Johnson & Johnson
6.1.12 Koninklijke Philips N.V.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS